- Home
- LGVN vs IGC Comparison
LGVN vs IGC Comparison
Compare LGVN & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- IGC
- Stock Information
- Founded
- LGVN 2014
- IGC 2005
- Country
- LGVN United States
- IGC United States
- Employees
- LGVN N/A
- IGC N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- LGVN Health Care
- IGC Health Care
- Exchange
- LGVN Nasdaq
- IGC Nasdaq
- Market Cap
- LGVN 23.4M
- IGC 20.2M
- IPO Year
- LGVN 2021
- IGC N/A
- Fundamental
- Price
- LGVN $1.35
- IGC $0.29
- Analyst Decision
- LGVN Strong Buy
- IGC Strong Buy
- Analyst Count
- LGVN 3
- IGC 2
- Target Price
- LGVN $8.67
- IGC $3.88
- AVG Volume (30 Days)
- LGVN 126.3K
- IGC 196.9K
- Earning Date
- LGVN 05-08-2025
- IGC 06-23-2025
- Dividend Yield
- LGVN N/A
- IGC N/A
- EPS Growth
- LGVN N/A
- IGC N/A
- EPS
- LGVN N/A
- IGC N/A
- Revenue
- LGVN $2,225,000.00
- IGC $1,236,000.00
- Revenue This Year
- LGVN $1.30
- IGC N/A
- Revenue Next Year
- LGVN $19.15
- IGC $16.45
- P/E Ratio
- LGVN N/A
- IGC N/A
- Revenue Growth
- LGVN 127.50
- IGC 1.65
- 52 Week Low
- LGVN $0.77
- IGC $0.25
- 52 Week High
- LGVN $6.40
- IGC $0.62
- Technical
- Relative Strength Index (RSI)
- LGVN 40.87
- IGC 46.51
- Support Level
- LGVN $1.30
- IGC $0.28
- Resistance Level
- LGVN $1.52
- IGC $0.32
- Average True Range (ATR)
- LGVN 0.13
- IGC 0.01
- MACD
- LGVN -0.02
- IGC -0.00
- Stochastic Oscillator
- LGVN 9.43
- IGC 26.50
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.